Match Group Inc vs Summit Therapeutics Inc — how do they compare? Match Group Inc trades at $36.49 (market cap $8.45B), while Summit Therapeutics Inc trades at $15.35 (market cap $12.06B). The key difference: Summit Therapeutics Inc is the larger of the two by market cap, and Match Group Inc pays a 2.17% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| MTCH | SMMT | |
|---|---|---|
Market Cap | $8.45B | $12.06B |
Sector | Media | Health |
52-Week High | $41.24 | $26.98 |
52-Week Low | $28.90 | $12.55 |
Enterprise Value | $11.42B | $11.39B |
Dividend Yield | 2.17% | — |
Signals from Pluang's Aura AI — not financial advice
MTCH trades at $36.73, down 1.42% amid mixed technical signals and recent earnings volatility. The stock shows bearish momentum with key support at $35, while fundamentals reveal strong profitability with 74.8% gross margins and 20.17% net income margin. Recent Q2 2026 earnings missed revenue estimates despite Tinder engagement improvements, creating investor uncertainty about near-term growth.
MTCH presents a value opportunity with attractive P/E of 13.05 and analyst consensus target of $42.33 (15% upside), but faces execution risks in Tinder's turnaround and high debt load. The 53% buy rating reflects optimism for Hinge growth and margin expansion, though quarterly volatility requires careful monitoring of user trends and competitive pressures.
Summit Therapeutics (SMMT) trades at $15.42, up 3.7% with a bullish technical signal. The company shows negative profitability with ROE at -192.5% and net loss of $1.08B for 2025, but maintains positive analyst sentiment with 14 buy ratings and a $27.90 consensus price target. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials.
The investment case hinges on ivonescimab's regulatory approval potential, offering significant upside if successful. However, substantial risks include ongoing losses, cash burn requiring financing, and regulatory uncertainty. Current technical strength suggests momentum, but fundamental challenges require careful risk assessment for speculative biotech investors.
Trailing returns across standard periods
Match Group is a provider of online dating products. The firm became public in 2015 and was more than 80% owned by IAC/InterActiveCorp until IAC spun it off in the second quarter of 2020. The company has a vast portfolio of different online dating service providers, including Tinder, Match.com, OkCupid, Plenty of Fish, and Meetic. Match Group has more than 45 brands of online dating sites and/or apps, from which it generates user fee revenue (95%) and advertising revenue (5%).
Read more on MTCH →Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →